Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance

Abstract Background Non-small cell lung cancer (NSCLC) patients with activating EGFR mutations initially respond to first-generation EGFR inhibitors; however, the efficacy of these drugs is limited by acquired resistance driven by the EGFR T790M mutation. The discovery of third-generation EGFR inhib...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Tao Zhang, Rong Qu, Shingpan Chan, Mengzhen Lai, Linjiang Tong, Fang Feng, Hongyu Chen, Tingting Song, Peiran Song, Gang Bai, Yingqiang Liu, Yanan Wang, Yan Li, Yi Su, Yanyan Shen, Yiming Sun, Yi Chen, Meiyu Geng, Ke Ding, Jian Ding, Hua Xie
Формат: Artigo
Язык:Inglês
Опубликовано: BMC 2020-05-01
Серии:Molecular Cancer
Предметы:
Non-small cell lung cancer (NSCLC)
EGFR T790M
Small-molecule inhibitor
Drug resistance
Ack1
Online-ссылка:http://link.springer.com/article/10.1186/s12943-020-01202-9
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы